Clinical Trial Update: Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating dapsone as a steroid-sparing agent for Pemphigus vulgaris has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pemphigus Vulgaris

Drugs mentioned

• DAPSONE (dapsone)

Snippet

Sponsor: Jacobus Pharmaceutical | Conditions: Pemphigus Vulgaris | Phase 2 | Status: TERMINATED